Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Pancreatic Beta-Cell Protection Market by Type (Stem Cell Based, Gene Therapies, RNA Based Therapies, Monoclonal Antibodies (MAbs), Phytotherapy), By Application (Hospital, Medical Research Laboratory, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Pancreatic Beta-Cell Protection Market by Type (Stem Cell Based, Gene Therapies, RNA Based Therapies, Monoclonal Antibodies (MAbs), Phytotherapy), By Application (Hospital, Medical Research Laboratory, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 168364 3300 Medical Devices & Consumables 377 241 Pages 4.7 (35)
                                          

Industry Growth Insights published a new data on “Pancreatic Beta-Cell Protection Market”. The research report is titled “Pancreatic Beta-Cell Protection Market research by Types (Stem Cell Based, Gene Therapies, RNA Based Therapies, Monoclonal Antibodies (MAbs), Phytotherapy), By Applications (Hospital, Medical Research Laboratory, Others), By Players/Companies ViaCyte, PharmaCyte Biotech, Boehringer Ingelheim, GalaxoSmithKline, Beta-Cell NV, Novartis, Janssen Research & Development, Pfizer Inc, BioLineRx, Genentech, Novo Nordisk, Sanofi, Osiris Therapeutics, Beta-O2 Technologies Ltd, Transition Therapeutics”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Pancreatic Beta-Cell Protection Market Research Report

By Type

Stem Cell Based, Gene Therapies, RNA Based Therapies, Monoclonal Antibodies (MAbs), Phytotherapy

By Application

Hospital, Medical Research Laboratory, Others

By Companies

ViaCyte, PharmaCyte Biotech, Boehringer Ingelheim, GalaxoSmithKline, Beta-Cell NV, Novartis, Janssen Research & Development, Pfizer Inc, BioLineRx, Genentech, Novo Nordisk, Sanofi, Osiris Therapeutics, Beta-O2 Technologies Ltd, Transition Therapeutics

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

241

Number of Tables & Figures

169

Customization Available

Yes, the report can be customized as per your need.


Global Pancreatic Beta-Cell Protection Industry Outlook


Global Pancreatic Beta-Cell Protection Market Report Segments:

The global Pancreatic Beta-Cell Protection market is segmented on the basis of:

Types

Stem Cell Based, Gene Therapies, RNA Based Therapies, Monoclonal Antibodies (MAbs), Phytotherapy

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospital, Medical Research Laboratory, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. ViaCyte
  2. PharmaCyte Biotech
  3. Boehringer Ingelheim
  4. GalaxoSmithKline
  5. Beta-Cell NV
  6. Novartis
  7. Janssen Research & Development
  8. Pfizer Inc
  9. BioLineRx
  10. Genentech
  11. Novo Nordisk
  12. Sanofi
  13. Osiris Therapeutics
  14. Beta-O2 Technologies Ltd
  15. Transition Therapeutics

Global Pancreatic Beta-Cell Protection Market Overview


Highlights of The Pancreatic Beta-Cell Protection Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Stem Cell Based
    2. Gene Therapies
    3. RNA Based Therapies
    4. Monoclonal Antibodies (MAbs)
    5. Phytotherapy
  1. By Application:

    1. Hospital
    2. Medical Research Laboratory
    3. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Pancreatic Beta-Cell Protection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Pancreatic Beta-Cell Protection Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Pancreatic beta-cells are responsible for producing insulin. Insulin is a hormone that helps the body process and use glucose from food. When pancreatic beta-cells are damaged, they may not be able to produce enough insulin to keep the body's blood sugar levels in check. This can lead to diabetes or other health problems.

Some of the major companies in the pancreatic beta-cell protection market are ViaCyte, PharmaCyte Biotech, Boehringer Ingelheim, GalaxoSmithKline, Beta-Cell NV, Novartis, Janssen Research & Development, Pfizer Inc, BioLineRx, Genentech, Novo Nordisk, Sanofi, Osiris Therapeutics, Beta-O2 Technologies Ltd, Transition Therapeutics.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Pancreatic Beta-Cell Protection Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Pancreatic Beta-Cell Protection Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Pancreatic Beta-Cell Protection Market - Supply Chain
   4.5. Global Pancreatic Beta-Cell Protection Market Forecast
      4.5.1. Pancreatic Beta-Cell Protection Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Pancreatic Beta-Cell Protection Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Pancreatic Beta-Cell Protection Market Absolute $ Opportunity

5. Global Pancreatic Beta-Cell Protection Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Type
      5.3.1. Stem Cell Based
      5.3.2. Gene Therapies
      5.3.3. RNA Based Therapies
      5.3.4. Monoclonal Antibodies (MAbs)
      5.3.5. Phytotherapy
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Pancreatic Beta-Cell Protection Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Application
      6.3.1. Hospital
      6.3.2. Medical Research Laboratory
      6.3.3. Others
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Pancreatic Beta-Cell Protection Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Pancreatic Beta-Cell Protection Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Pancreatic Beta-Cell Protection Demand Share Forecast, 2019-2026

9. North America Pancreatic Beta-Cell Protection Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Application
      9.4.1. Hospital
      9.4.2. Medical Research Laboratory
      9.4.3. Others
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Type
      9.7.1. Stem Cell Based
      9.7.2. Gene Therapies
      9.7.3. RNA Based Therapies
      9.7.4. Monoclonal Antibodies (MAbs)
      9.7.5. Phytotherapy
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Pancreatic Beta-Cell Protection Demand Share Forecast, 2019-2026

10. Latin America Pancreatic Beta-Cell Protection Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Application
      10.4.1. Hospital
      10.4.2. Medical Research Laboratory
      10.4.3. Others
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Type
      10.7.1. Stem Cell Based
      10.7.2. Gene Therapies
      10.7.3. RNA Based Therapies
      10.7.4. Monoclonal Antibodies (MAbs)
      10.7.5. Phytotherapy
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Pancreatic Beta-Cell Protection Demand Share Forecast, 2019-2026

11. Europe Pancreatic Beta-Cell Protection Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Application
      11.4.1. Hospital
      11.4.2. Medical Research Laboratory
      11.4.3. Others
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Type
      11.7.1. Stem Cell Based
      11.7.2. Gene Therapies
      11.7.3. RNA Based Therapies
     11.7.4. Monoclonal Antibodies (MAbs)
      11.7.5. Phytotherapy
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Pancreatic Beta-Cell Protection Demand Share, 2019-2026

12. Asia Pacific Pancreatic Beta-Cell Protection Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Application
      12.4.1. Hospital
      12.4.2. Medical Research Laboratory
      12.4.3. Others
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Type
      12.7.1. Stem Cell Based
      12.7.2. Gene Therapies
      12.7.3. RNA Based Therapies
      12.7.4. Monoclonal Antibodies (MAbs)
      12.7.5. Phytotherapy
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Pancreatic Beta-Cell Protection Demand Share, 2019-2026

13. Middle East & Africa Pancreatic Beta-Cell Protection Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Application
      13.4.1. Hospital
      13.4.2. Medical Research Laboratory
      13.4.3. Others
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Pancreatic Beta-Cell Protection Market Size and Volume Forecast by Type
      13.7.1. Stem Cell Based
      13.7.2. Gene Therapies
      13.7.3. RNA Based Therapies
      13.7.4. Monoclonal Antibodies (MAbs)
      13.7.5. Phytotherapy
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Pancreatic Beta-Cell Protection Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Pancreatic Beta-Cell Protection Market: Market Share Analysis
   14.2. Pancreatic Beta-Cell Protection Distributors and Customers
   14.3. Pancreatic Beta-Cell Protection Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. ViaCyte
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. PharmaCyte Biotech
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Boehringer Ingelheim
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. GalaxoSmithKline
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Beta-Cell NV
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Novartis
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Janssen Research & Development
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Pfizer Inc
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. BioLineRx
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Genentech
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Novo Nordisk
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. Sanofi
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. Osiris Therapeutics
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. Beta-O2 Technologies Ltd
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. Transition Therapeutics
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us